Year: 2021

Potential to add third clinical-stage program to oncology pipeline Progressing patient enrolment towards interim analyses in lisavanbulin phase 2 study and in patient cohorts in FIDES-01 and FIDES-02 studies with derazantinibBasel, Switzerland, November 16, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), to start clinical studies with the company’s novel drug candidate BAL0891 in cancer therapy. BAL0891 is a potential first-in-class small-molecule kinase inhibitor. If the IND is granted, Basilea plans to initiate a phase 1 study in patients with advanced solid tumors in the first quarter...

PRESS RELEASE: 16 November 2021, 07:00 CET New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer Mechelen, Belgium, 16 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a new study1 that demonstrates that the Idylla™ EGFR Mutation Test (CE-IVD) running on Biocartis’ molecular diagnostics Idylla™ platform improves patient management decisions for patients with non-small cell lung cancer (NSCLC) through the faster screening of EGFR mutations. Nearly 85% of lung cancers are non-small cell lung cancers2. EGFR or ‘Epidermal Growth Factor Receptor’ mutations are the second most common cancer driver mutation in NSCLC. EGFR testing...

The shares in Belships ASA will be traded ex dividend NOK 0.55 from today, 16 November 2021. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

AS Inbank is planning a subordinated bonds programme in a total amount of up to 35 million euros to be issued in several series over the next 36 months. In the first series under the bond programme, Inbank plans to issue subordinated bonds in a total amount of 12 million euros with an option to increase the issue to a maximum of 18 million euros. The maturity date of the bonds is 10 years with the issuer having a premature redemption right after 5 years. The subscription period of the first series is scheduled for 30 November – 9 December 2021. The bonds will be listed on the Nasdaq Tallinn Stock Exchange by the end of 2021.  The public offering is to be carried out in Estonia only, provided that the Financial Supervision Authority has registered the prospectus. Inbank will announce the registration of the prospectus and the commencement...

GUANGZHOU, China, Nov. 15, 2021 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 28, 2021 at 10:00 a.m. (local time) at the Company’s Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai and Cleary Gottlieb Steen & Hamilton (Hong Kong) at 37/F, Hysan Place, 500 Hennessy Road, Causeway Bay, Hong Kong. The AGM will be held for the following proposals:To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2021 and to authorize the directors of the Company to determine the remuneration...

BEIJING, Nov. 16, 2021 (GLOBE NEWSWIRE) — China Index Holdings Limited (NASDAQ: CIH) (“CIH” or the “Company”), a leading real estate information and analytics service platform provider in China, today announced that it had filed its annual report on Form 20-F for the year ended December 31, 2020 (the “annual report”) with the U.S. Securities and Exchange Commission (the “SEC”) on November 15, 2021. The annual report, which contains the Company’s audited combined and consolidated financial statements, can be accessed on the SEC’s website at http://www.sec.gov as well as through the Company’s investor relations website at http://ir.chinaindexholdings.com. Hard copies of the annual report are available, free of charge, to shareholders upon request. About CIH CIH operates a leading real estate information and analytics service platform...